Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer

A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes

“…Amplification of 8p11-12 is a well documented event in breast tumors, but the relevant oncogene for the region has not been clearly elucidated (Theillet et al, 1993;Ugolini et al, 1999). The FGFR1 gene, which belongs to the fibroblast growth factor receptor family, has been long considered a strong candidate oncogene for the amplicon (Theillet et al, 1993;Adelaide et al, 1998;Ugolini et al, 1999). However, functional analysis has failed to provide direct evidence of an oncogenic role for FGFR1 and its importance as a driver of the amplicon has been questioned (Ray et al, 2004).…”

Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers

“…Aberrant centrosome activity and structure (Lingle and Salisbury, 1999) have been associated with tumor progression. Despite the absence of previous documentation of PCM1 involvement in breast carcinogenesis, loss of heterozygosity has been detected in between 33 and 42% of breast cancer samples using the intragenic microsatellite marker D8S261 (Adelaide et al, 1998;Yokota et al, 1999;Sigbjornsdottir et al, 2000;Charafe-Jauffret et al, 2002). Importantly, we demonstrate loss of PCM1 protein in a similar number (31%) of breast cancer samples, many of which showed concomitant reduced gene copy number by FISH.…”

γ-Heregulin has no biological significance in primary breast cancer

“…Chromosome 8p abnormalities have been associated with the development and/or progression of breast cancer and 8p22 deletions have been associated with more aggressive phenotypes and poorer survival (Yokota et al, 1999;Utada et al, 2000). Amplification of the region 8p12, that contains the neuregulin (NRG-1, also denominated heregulin) gene, is detected in about 12% of breast tumours (Adélaïde et al, 1994(Adélaïde et al, , 1998Lee and Wood, 1993) and breakpoints in bands 8p11-p21 have been reported in breast cancer (Morris et al, 1997;Courtay-Cahen et al, 2000). The NRG-1 gene encodes, by alternative splicing or by initiation of gene transcripts at different sites, a family of more than 15 membrane bound or secreted proteins most of which contain an extracellular epidermal growth factor (EGF)-like domain (Peles and Yarden, 1993).…”